Literature DB >> 1140870

Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas.

M Lieber, J Mazzetta, W Nelson-Rees, M Kaplan, G Todaro.   

Abstract

An epithelioid cell line, started from a human pancreatic carcinoma of ductal cell origin, has been maintained in culture for over 2 years and has been subcultured more than 40 times. The PANC-1 cell line has a doubling time of 52 h and G6PD activity of the slow mobility of B type. Chromosome studies show a modal number of 63 with three distinct marker chromosomes and a small ring chromosome. The malignant nature of the PANC-1 cell line was verified by: (1) the ready growth of PANC-1 cells in soft agar and on top of a fibroblast monolayer; and (2) the formation of a progressively growing anaplastic carcinoma after injection of a nude-athymic mouse with PANC-1 cells.

Entities:  

Mesh：

Year:  1975        PMID： 1140870     DOI： 10.1002/ijc.2910150505

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


  179 in total

1.  Development and functional characterization of insulin-releasing human pancreatic beta cell lines produced by electrofusion.

Authors:  Jane T McCluskey; Muhajir Hamid; Hong Guo-Parke; Neville H McClenaghan; Ramon Gomis; Peter R Flatt
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

2.  Chemical screen identifies FDA-approved drugs and target pathways that induce precocious pancreatic endocrine differentiation.

Authors:  Meritxell Rovira; Wei Huang; Shamila Yusuff; Joong Sup Shim; Anthony A Ferrante; Jun O Liu; Michael J Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-14       Impact factor: 11.205

3.  In vivo factors influencing tumour M2-pyruvate kinase level in human pancreatic cancer cell lines.

Authors:  Yogesh Kumar; Sybille Mazurek; Shiyu Yang; Klaus Failing; Marc Winslet; Barry Fuller; Brian R Davidson
Journal:  Tumour Biol       Date:  2010-02-24

4.  Differential mucin gene expression in human pancreatic and colon cancer cells.

Authors:  S Yonezawa; J C Byrd; R Dahiya; J J Ho; J R Gum; B Griffiths; D M Swallow; Y S Kim
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

5.  Effects of a histone deacetylase inhibitor, sodium butyrate, on 53-kDa protein expression and sensitivity to anticancer drugs of pancreatic cancer cells.

Authors:  Masaki Kitazono; Hiroyuki Shinchi; Sumiya Ishigami; Shinichi Ueno; Shoji Natsugoe
Journal:  Curr Ther Res Clin Exp       Date:  2010-06

6.  A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice.

Authors:  B J Drucker; F M Marincola; D Y Siao; T A Donlon; C D Bangs; W D Holder
Journal:  In Vitro Cell Dev Biol       Date:  1988-12

7.  Integrin α6β4 Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF).

Authors:  Brittany L Carpenter; Min Chen; Teresa Knifley; Kelley A Davis; Susan M W Harrison; Rachel L Stewart; Kathleen L O'Connor
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

8.  Secretion granules of transplantable pancreatic acinar carcinoma of rat.

Authors:  J K Reddy; M K Reddy; L J Hansen; S A Qureshi
Journal:  Biochem J       Date:  1980-06-15       Impact factor: 3.857

9.  Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model.

Authors:  Weijing Cai; Ranjala Ratnayake; Michael H Gerber; Qi-Yin Chen; Yichao Yu; Hartmut Derendorf; Jose G Trevino; Hendrik Luesch
Journal:  Invest New Drugs       Date:  2018-08-03       Impact factor: 3.850

10.  A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.

Authors:  Jianliang Zhang; Di-Hua He; Maria Zajac-Kaye; Steven N Hochwald
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.